CDKN2A and familial pancreatic carcinoma: For instance, a study conducted by Lynch H.T. et al. in 2008 showed data indicating a 13–22-fold elevation in the risk of pancreatic cancer development in individuals with familial melanoma, and those with p16/CDKN2A mutations exhibited a 38-fold increased risk of pancreatic cancer compared to the general population [11].